Dova Pharmaceuticals (DOVA) Shares Down 12.5%

Dova Pharmaceuticals Inc (NASDAQ:DOVA)’s share price traded down 12.5% during mid-day trading on Friday . The stock traded as low as $16.63 and last traded at $16.89. 647,924 shares traded hands during mid-day trading, an increase of 207% from the average session volume of 211,005 shares. The stock had previously closed at $19.30.

Several equities analysts recently issued reports on the company. BidaskClub raised Dova Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 31st. Raymond James assumed coverage on Dova Pharmaceuticals in a research report on Wednesday, August 29th. They issued an “outperform” rating and a $44.00 price objective on the stock. Leerink Swann lowered their price objective on Dova Pharmaceuticals from $32.00 to $31.00 and set a “market perform” rating on the stock in a research report on Tuesday, September 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dova Pharmaceuticals in a research report on Sunday, July 15th. Finally, Zacks Investment Research cut Dova Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $33.20.

The stock has a market cap of $530.20 million, a PE ratio of -12.07 and a beta of 0.87. The company has a quick ratio of 13.14, a current ratio of 13.19 and a debt-to-equity ratio of 0.17.

Dova Pharmaceuticals (NASDAQ:DOVA) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.12. The business had revenue of $2.93 million during the quarter, compared to the consensus estimate of $2.66 million. Equities analysts predict that Dova Pharmaceuticals Inc will post -2.76 EPS for the current year.

In other Dova Pharmaceuticals news, CEO Alex Sapir acquired 21,700 shares of the stock in a transaction that occurred on Tuesday, August 14th. The shares were acquired at an average cost of $22.83 per share, with a total value of $495,411.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 55.50% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in shares of Dova Pharmaceuticals by 81.3% during the 2nd quarter. Bank of America Corp DE now owns 5,305 shares of the company’s stock valued at $159,000 after buying an additional 2,379 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Dova Pharmaceuticals by 148.6% during the 1st quarter. JPMorgan Chase & Co. now owns 5,345 shares of the company’s stock valued at $145,000 after buying an additional 3,195 shares during the period. Metropolitan Life Insurance Co. NY bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $128,000. MetLife Investment Advisors LLC bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $181,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of Dova Pharmaceuticals during the 2nd quarter valued at $215,000. 36.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was originally posted by WKRB News and is the property of of WKRB News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.wkrb13.com/2018/11/10/dova-pharmaceuticals-dova-shares-down-12-5.html.

About Dova Pharmaceuticals (NASDAQ:DOVA)

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead drug candidate is avatrombopag that has completed Phase III clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease.

Featured Story: Understanding Analyst Ratings

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply